ArticleAmerican journal of translational research2025
Serum biomarkers for diagnosis and severity evaluation in knee osteoarthritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the serum levels of signal transducer and activator of transcription 3 (STAT3), vascular endothelial growth factor (VEGF), and interleukins (IL)-2 and IL-4 in patients with knee osteoarthritis (KOA), and to evaluate their diagnostic value for disease severity.
methodsA total of 115 KOA patients and 50 healthy controls were enrolled. Serum levels of STAT3, VEGF, IL-2, and IL-4 were measured in all participants. The correlations between these biomarkers and KOA severity were further analyzed.
resultsCompared to healthy controls, KOA patients exhibited significantly elevated serum levels of STAT3, VEGF, IL-2, and IL-4 (all P < 0.05). Following standard treatment, the concentrations of these biomarkers significantly decreased. Receiver operating characteristic (ROC) curve analysis revealed that the area under the curve (AUC) values for diagnosing KOA were 0.710 for STAT3, 0.726 for VEGF, 0.704 for IL-2, and 0.797 for IL-4. Furthermore, the serum concentrations of these factors showed strong positive correlations with KOA severity (r = 0.436 for STAT3, r = 0.467 for VEGF, r = 0.497 for IL-2, and r = 0.509 for IL-4). Their AUC values for assessing disease severity were 0.723 (STAT3), 0.742 (VEGF), 0.769 (IL-2), and 0.757 (IL-4). Combined detection of these biomarkers improved diagnostic accuracy.
conclusionsAbnormally elevated serum levels of STAT3, VEGF, IL-2, and IL-4 in KOA patients are closely associated with disease severity and treatment efficacy. These biomarkers may serve as auxiliary indicators for KOA diagnosis and severity assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.